Will Novavax Hit $250 This Year?

Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone. Investors' views of the biotech have fluctuated along with news surrounding the pandemic, as well as what some of its competitors in the COVID-19 vaccine market are up to.

But despite Novavax's recent issues, Wall Street has high hopes for the stock. The company's average one-year price target currently stands at a whopping $250, according to Yahoo! Finance. Meanwhile, Novavax's shares are trading at $95.22. Can the company hit this mark within the next 12 months?

Continue reading

Source Fool.com